# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Baird analyst Eric Coldwell maintains Charles River (NYSE:CRL) with a Outperform and lowers the price target from $271 to $239.
Critical starting material manufacture for therapeutic targeting high unmet need ophthalmology indicationCharles River Laborato...
Barclays analyst Luke Sergott initiates coverage on Charles River (NYSE:CRL) with a Equal-Weight rating and announces Price ...
Argus Research analyst David Toung downgrades Charles River (NYSE:CRL) from Buy to Hold.
Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancersCharles River Laboratories Int...